Searched for: in-biosketch:true
person:velchv01
Programmed death ligand-1 expression in non-small cell lung cancer
Velcheti, Vamsidhar; Schalper, Kurt A; Carvajal, Daniel E; Anagnostou, Valsamo K; Syrigos, Konstantinos N; Sznol, Mario; Herbst, Roy S; Gettinger, Scott N; Chen, Lieping; Rimm, David L
Recent strategies targeting the interaction of the programmed cell death ligand-1 (PD-L1, B7-H1, CD274) with its receptor, PD-1, resulted in promising activity in early phase clinical trials. In this study, we used various antibodies and in situ mRNA hybridization to measure PD-L1 in non-small cell lung cancer (NSCLC) using a quantitative fluorescence (QIF) approach to determine the frequency of expression and prognostic value in two independent populations. A control tissue microarray (TMA) was constructed using PD-L1-transfected cells, normal human placenta and known PD-L1-positive NSCLC cases. Only one of four antibodies against PD-L1 (5H1) validated for specificity on this TMA. In situ PD-L1 mRNA using the RNAscope method was similarly validated. Two cohorts of NSCLC cases in TMAs including 340 cases from hospitals in Greece and 204 cases from Yale University were assessed. Tumors showed PD-L1 protein expression in 36% (Greek) and 25% (Yale) of the cases. PD-L1 expression was significantly associated with tumor-infiltrating lymphocytes in both cohorts. Patients with PD-L1 (both protein and mRNA) expression above the detection threshold showed statistically significant better outcome in both series (log-rank P=0.036 and P=0.027). Multivariate analysis showed that PD-L1 expression was significantly associated with better outcome independent of histology. Measurement of PD-L1 requires specific conditions and some commercial antibodies show lack of specificity. Expression of PD-L1 protein or mRNA is associated with better outcome. Further studies are required to determine the value of this marker in prognosis and prediction of response to treatments targeting this pathway.
PMCID:6125250
PMID: 24217091
ISSN: 1530-0307
CID: 3237472
Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1)
Velcheti, Vamsidhar; Rimm, David L; Schalper, Kurt A
Programmed death-1 (PD-1) is a coinhibitory inducible receptor present on T-cells and macrophages. Tumor cells with increased programmed death ligand-1 (PD-L1) are believed to escape immunity through activation of PD-1/PD-L1 pathway and suppression of effector-immune responses. Recent strategies targeting the PD-1/PD-L1 axis have shown promising results in patients with several tumors types, including lung carcinomas. Preliminary data suggest that PD-L1 protein expression might have predictive response to such therapies. Sarcomatoid carcinomas (SCs) of the lung include rare subtypes of poorly differentiated non-small-cell lung carcinomas of high grade and aggressive behavior. The biology of these neoplasms is poorly understood and they frequently show increased local inflammatory and lymphocytic infiltration. Here, we report the expression of PD-L1 in 13 SCs from two large retrospective lung cancer cohorts. Using automated quantitative immunofluoresence and a mouse monoclonal antibody directed against the extracellular domain of PD-L1, we show that 9 of 13 patients (69.2%) with SCs are positive for PD-L1 and their levels are higher than in conventional non-small-cell lung carcinoma. These results provide rationale for the potential use of targeted immunotherapy in lung SCs.
PMCID:3703468
PMID: 23676558
ISSN: 1556-1380
CID: 3237462
High SOX2 levels predict better outcome in non-small cell lung carcinomas
Velcheti, Vamsidhar; Schalper, Kurt; Yao, Xiaopan; Cheng, Huan; Kocoglu, Mehmet; Dhodapkar, Kavita; Deng, Yanhong; Gettinger, Scott; Rimm, David L
BACKGROUND:SOX2 is an embryonic developmental transcription factor, which is important in the development of the respiratory tract. SOX2 overexpression is associated with aggressive disease in several tumor types. However, SOX2 overexpression and gene amplification associates with favorable outcome in lung squamous cell carcinomas (SCC) and dissimilar results have been reported in lung adenocarcinomas (ADC). The aim of the present study was to evaluate SOX2 expression in NSCLC and determine the relationship with clinico-pathological variables and outcome. METHODS:SOX2 protein levels were measured in tissue microarrays (TMAs) containing FFPE samples from two independent lung cancer cohorts (n = 340 & 307) using automated quantitative immunofluorescence (QIF). Assay validation was performed using FFPE preparations of cell lines with known SOX2 expression. Associations of SOX2 levels with main clinico-pathological characteristics and with overall survival were studied using uni-and multivariate analysis. RESULTS:SOX2 levels were higher in patients with SCC than in ADC in both cohorts (p value<0.0001). In the training cohort, NSCLC patients whose tumors showed high SOX2 (n = 245) had longer survival than those with low SOX2 levels (log rank p = 0.0002). Comparable results were observed in the second independent validation cohort, log rank p = 0.0113. SOX2 positive cases showed a 58% reduction in risk of death in Cox univariate analysis (hazards ratio-HR = 0.42 confidence interval-CI (0.36,0.73), p = 0.0002). SOX2 was associated with significantly longer survival independent of histology in multivariate analysis (hazards ratio-HR = 0.429 confidence interval-CI (0.295, 0.663), p = <0.001). CONCLUSIONS:SOX2 is an independent positive prognostic marker in NSCLC. Increased SOX2 levels are more frequent in SCC than in ADC, but the association with better survival is independent from the histological subtype.
PMCID:3631238
PMID: 23620753
ISSN: 1932-6203
CID: 3237452
Management of patients with advanced non-small cell lung cancer: role of gefitinib
Velcheti, Vamsidhar; Morgensztern, Daniel; Govindan, Ramaswamy
Gefitinib is the first epidermal growth factor receptor tyrosine-kinase inhibitor approved for the treatment of advanced non-small cell lung cancer (NSCLC). Its failure to improve survival in a placebo-control study, however, led to its withdrawal in the United States though it is available in many other countries Subsequent studies nevertheless showed comparable efficacy for gefitinib and docetaxel in the second-line therapy. Gefitinib significantly improved progression-free survival compared to chemotherapy in patients with activating mutations in the epidermal growth factor receptor tyrosine kinase mutations. This review will discuss the results of these large randomized studies and discuss the role of gefitinib in the treatment of advanced NSCLC.
PMCID:2880342
PMID: 20531966
ISSN: 1177-5491
CID: 3237432
Prelinical Evaluation of Lyn Kinase Inhibition for the Treatment of B Cell Chronic Lymphocytic Leukemia (B-CLL). [Meeting Abstract]
Velcheti, Vamsidhar; Li, Li; Philips, Joseph; Fuloria, Jyotsna; Rodwig, Francis R.; Cole, John T.; Samaniego, Felipe; Prakash, Om
ISI:000272725804112
ISSN: 0006-4971
CID: 3238032
Protein kinase C-epsilon (PKC-\#949;) is an important component of the Lyn kinase signaling pathway. [Meeting Abstract]
Swamy, Rama; Velcheti, Vamsidhar; Prakash, Om
ISI:000209701803009
ISSN: 0008-5472
CID: 3237922
Absence of mutations in the epidermal growth factor receptor (EGFR) kinase domain in patients with mesothelioma [Letter]
Velcheti, Vamsidhar; Kasai, Yumi; Viswanathan, Avinash K; Ritter, Jon; Govindan, Ramaswamy
PMID: 19333077
ISSN: 1556-1380
CID: 3237422
Protein Kinase C-Epsilon Is An Important Component of the Lyn Kinase Signaling Pathway in the Apoptotic Resistance of B-Chronic Lymphocytic Leukemia Cells [Meeting Abstract]
Velcheti, Vamsidhar; Tamma, Srikanth; Larned, Zoe L.; Fuloria, Jyotsna; Li, Li; Rodwig, Francis R.; Cole, John T.; Samaniego, Felipe; Prakash, Om
ISI:000262104702420
ISSN: 0006-4971
CID: 3238012
Pathogenesis of prostate cancer: lessons from basic research
Velcheti, Vamsidhar; Karnik, Satish; Bardot, Stephen F; Prakash, Om
In the United States, prostate cancer is the second most common cause of cancer-related deaths in men. While the importance of androgens and androgen receptors (ARs) in primary prostate cancer is well established, the role of ARs in prostate cancers that emerge despite androgen ablation therapies remains poorly understood. The aim of this article is to illustrate the fundamental biology of prostate cancer. We focus mainly on the AR because of its critical role in the progression and metastatic spread of prostate cancer. We also summarize the alternate pathways that may potentially contribute to the progression of prostate cancer. Identifying the underlying mechanisms of androgen independence is crucial in the design of appropriate therapies for hormone-refractory neoplasms.
PMCID:3096366
PMID: 21603505
ISSN: 1524-5012
CID: 3237442
Presentation and stage-specific outcomes of lifelong never-smokers with non-small cell lung cancer (NSCLC)
Subramanian, Janakiraman; Velcheti, Vamsidhar; Gao, Feng; Govindan, Ramaswamy
BACKGROUND:Tobacco smoking leads to lung cancer. Approximately 10% of patients with lung cancer are life long never-smokers. There are only limited data available on the clinical characteristics and outcomes of lung cancer in never-smokers from the Western hemisphere. METHODS:Demographic and survival information was collected on 254 never-smokers with a confirmed pathologic diagnosis of non-small cell lung cancer (NSCLC) by reviewing their medical records and the Social Security database. RESULTS:The study population consisted of 182 (71.6%) women and 72 (28.3%) men. The median age was 70 years (range: 31-91 years). Adenocarcinoma was the most common histology accounting for 60.8% of all patients, followed by NSCLC not otherwise specified (14.4%), bronchoalveolar carcinoma (13.6%), squamous cell carcinoma (8.8%), and large-cell type (2.4%). Majority of patients presented with stage III or IV disease (62.5%). We compared survival between never-smokers and smokers with NSCLC matched for gender, histology, tumor stage, and years of diagnosis. No significant difference in 5-year survival was seen between never-smokers (27.2%) and smokers with NSCLC (31.3%; p = 0.73). CONCLUSIONS:Two thirds of patients with lung cancer who report no history of tobacco smoking are women. In the matched case-control analysis, we report no significant survival difference between lung cancer in never-smokers and those with history of tobacco smoking and lung cancer.
PMID: 17805060
ISSN: 1556-1380
CID: 3237402